Alumier Md Acne Balancing Serum

Description

No relevant information is available for SPL code 34089-3.

Uses and Indications

This drug is indicated for the treatment of acne.

There are no teratogenic or nonteratogenic effects mentioned in the available data.

Dosage and Administration

For adults aged 18 years and older, it is essential to cleanse the skin thoroughly prior to the application of the product.

New users should initiate treatment by applying the product to a small area once daily for three consecutive days to assess for any sensitivity. If no discomfort is experienced during this testing period, the user may proceed to cover the entire affected area with a thin layer of the product.

The recommended starting regimen involves one application daily, with the possibility of gradually increasing the frequency to two to three times daily, based on individual needs. Should the user experience dryness or peeling, it is advised to reduce the application frequency to once daily or every other day to mitigate these effects.

Contraindications

Use is contraindicated in patients who experience severe irritation, burning, or itching of the skin, hives, swelling of the eyes and mouth, blistering, or difficulty breathing. In such cases, discontinuation of use and consultation with a healthcare professional is advised.

Additionally, the product should not be used in individuals with severe acne or when improvement is not observed within 6-8 weeks of treatment.

Contact with the eyes should be avoided; if contact occurs, the eyes must be rinsed thoroughly with water.

Concurrent use of another topical acne product may increase the risk of skin irritation and dryness; therefore, only one topical acne product should be used at a time to minimize these risks.

Warnings and Precautions

For external use only. Healthcare professionals should advise patients to avoid contact with the eyes during application. In the event of accidental contact, it is imperative to rinse the eyes thoroughly with water to mitigate potential irritation.

When utilizing this product, it is important to note that the concurrent use of other topical acne treatments may increase the likelihood of skin irritation and dryness. Therefore, patients should be counseled to use only one topical acne product at a time to minimize the risk of adverse effects.

Patients should be instructed to discontinue use and consult a healthcare provider if they experience severe irritation, burning, or itching of the skin, as well as symptoms such as hives, swelling of the eyes and mouth, blistering, or difficulty breathing. Additionally, if patients have severe acne or do not observe any improvement within 6 to 8 weeks of treatment, they should seek medical advice.

It is crucial to keep this product out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or contact with a Poison Control Center should be made without delay.

Side Effects

Patients using this product should be aware that it is for external use only. Contact with the eyes should be avoided; in the event of contact, the affected area should be rinsed thoroughly with water.

Common adverse reactions include skin irritation and dryness, which are more likely to occur if another topical acne product is used concurrently. In such cases, it is advised to use only one topical acne product at a time to minimize the risk of irritation.

Patients are instructed to stop use and consult a doctor if they experience severe irritation, burning or itching of the skin, hives, swelling of the eyes and mouth, blistering, or difficulty breathing. Additionally, if patients have severe acne and do not observe improvement within 6 to 8 weeks, they should seek medical advice.

It is important to keep this product out of reach of children. In the event of accidental ingestion, medical help should be sought immediately, or contact with a Poison Control Center should be made without delay.

Drug Interactions

The concurrent use of multiple topical acne products may increase the risk of skin irritation and dryness. To minimize the potential for adverse effects, it is advised that only one topical acne product be used at a time. If irritation occurs, discontinuation of additional topical products is recommended to allow the skin to recover. Monitoring for signs of irritation is essential when initiating or adjusting treatment regimens involving topical acne therapies.

Packaging & NDC

Below are the non-prescription pack sizes of Alumier Md Acne Balancing Serum (salicylic acid). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or contact with a Poison Control Centre is recommended.

Geriatric Use

There is no specific information regarding the use of Alumier MD Acne Balancing Serum in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when considering this product for elderly patients, as the absence of data necessitates careful monitoring and individualized assessment of treatment risks and benefits in this population.

Pregnancy

There is no specific information available regarding the use of this medication during pregnancy, including safety concerns, dosage modifications, or special precautions. Healthcare professionals should consider the lack of data when prescribing this medication to pregnant patients. It is advisable to weigh the potential benefits against any unknown risks to fetal outcomes. Women of childbearing potential should be counseled on the importance of effective contraception during treatment.

Lactation

There are no specific warnings or recommendations regarding the use of this product in nursing mothers. Additionally, there is no information available about the potential for excretion in breast milk or any associated risks to breastfed infants.

Renal Impairment

There is no information available regarding dosage adjustments, special monitoring, or safety considerations for patients with renal impairment. Healthcare professionals should exercise caution and consider the lack of specific guidance when prescribing to patients with reduced kidney function.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in relation to the use of this medication. Consequently, there are no established dosage adjustments, special monitoring requirements, or precautions outlined for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be prudent in these cases, although specific parameters are not defined in the available information.

Overdosage

In the event of an overdosage, immediate medical assistance is crucial. If the substance is ingested, healthcare professionals should advise patients or caregivers to seek medical help or contact a Poison Control Center without delay.

Prompt intervention is essential to mitigate potential adverse effects associated with overdosage. Symptoms may vary depending on the specific substance involved, and healthcare providers should be prepared to assess and manage these symptoms accordingly.

Management procedures may include supportive care and symptomatic treatment, tailored to the individual patient's needs. Continuous monitoring and evaluation are recommended to ensure patient safety and effective resolution of any complications arising from the overdosage.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in these contexts.

Postmarketing Experience

Serious adverse reaction events associated with the use of this product have been reported voluntarily or through surveillance programs. Reports can be submitted to Alumier Labs Inc. at 550 Cochituate Road, Suite 25, Framingham, MA 01701.

Patient Counseling

Healthcare providers should advise patients to keep the product out of reach of children. Instruct patients that if the product is swallowed, they should seek medical help or contact a Poison Control Center immediately.

Patients should be informed to discontinue use and consult a doctor if they experience severe irritation, burning or itching of the skin, hives, swelling of the eyes and mouth, blistering, or difficulty breathing. Additionally, they should be advised to stop use and seek medical advice if they have severe acne or if improvement is not observed within 6 to 8 weeks of use.

It is important to instruct patients to avoid contact with the eyes while using this product. In the event of contact, they should rinse their eyes thoroughly with water.

Patients should also be made aware that skin irritation and dryness are more likely to occur if they use another topical acne product simultaneously. If irritation does occur, they should only use one topical acne product at a time to minimize the risk of adverse effects.

Storage and Handling

The product is supplied in a secure packaging format, with specific attention to maintaining the integrity of the contents. It is essential to store the product in a cool, dry place at room temperature to ensure optimal stability and efficacy.

Healthcare professionals are advised to inspect the packaging prior to use; the product should not be utilized if the security seal is broken or missing, as this may compromise the safety and effectiveness of the product.

Additional Clinical Information

No further data are available.

Drug Information (PDF)

This file contains official product information for Alumier Md Acne Balancing Serum, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)